Creative Medical Technology Holdings Inc. Common Stock (CELZ)
Stock · NASDAQ · Health Care
$0.75as of 10/16/2026
Price chart
Active signals
CELZ Signal Track Record
How signals performed across all stocks →What CELZ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -10.8% | 45% | September 21, 2026 |
| Bollinger Band Breakout | 22 | -8.8% | 27% | August 6, 2026 |
| Bollinger Band BreakdownActive now | 21 | -6.2% | 38% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -12.4% | 27% | November 7, 2025 |
| Any 20-session window (baseline) | -3.3% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CELZ
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 4
Fundamentals
- 1-day range
- $0.734$0.8493
- Market cap
- $7.58M
- P/E (trailing)
- —
- P/E (forward)
- -0.84
- EPS (trailing)
- $-1.97
- Dividend yield
- —
- Beta
- 1.92
- Avg. volume
- 6.76M
How Creative Medical Technology Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Creative Medical Technology Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- CRISCuris Inc. Common Stock$0.41▼ 19.61%Market cap $8.59MP/E —$0.465$33.6
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
- INABIN8bio Inc. Common Stock$1.11▼ 6.33%Market cap $9.55MP/E —$0.88$2.73
- VIVSVivoSim Labs Inc. Common Stock$0.16▼ 5.88%Market cap $5.53MP/E —$0.1495$3.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| CRIS Curis Inc. Common Stock | $8.59M | — | $0.41 | ▼ 19.61% | $0.465$33.6 |
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
| INAB IN8bio Inc. Common Stock | $9.55M | — | $1.11 | ▼ 6.33% | $0.88$2.73 |
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.16 | ▼ 5.88% | $0.1495$3.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%Benzinga · 9/25/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/22/2026
- Top movers in Monday's after hours sessionChartMill · 9/21/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/21/2026
- Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent FilingYahoo · 9/17/2026
- Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine PlatformBenzinga · 9/17/2026
- What's going on in today's after hours sessionChartMill · 9/14/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Warbington Timothy · September 24, 2026 · Grant1.00M
Institutional Ownership
March 31, 2026
- Total shares held
- 91.2K
- Total value held
- $188.0K
- Institutional holders
- 10
- Unknown38.3K
- Unknown20.4K
- Unknown14.3K
- Unknown10.5K
- Unknown5.0K
- Unknown2.1K
- Unknown534
- Unknown250
- Unknown1
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CELZ raises BioDefense stake to 80% with $200K cash and share purchase
Creative Medical Technology announced it has purchased an additional 4 million BioDefense shares for $200,000 in cash and 1 million of its own shares. The transaction raises Creative’s ownership of BioDefense to about 80 percent. The increased stake may broaden Creative’s product portfolio and could influence future earnings.
CELZ raises BioDefense stake to 80% with $200K cash and share purchase. Creative Medical Technology announced it has purchased an additional 4 million BioDefense shares for $200,000 in cash and 1 million of its own shares. The transaction raises Creative’s ownership of BioDefense to about 80 percent. The increased stake may broaden Creative’s product portfolio and could influence future earnings.